Breast Cancer

Sunitinib+Docetaxel Not Recommended for First-Line Treatment of HER2/neu Advanced Breast Cancer

The combination of sunitinib plus docetaxel improved the objective response rate (ORR) but did not prolong progression-free survival (PFS) or overall survival (OS) vs. docetaxel alone for the first-line treatment of HER2/neu-negative advanced breast cancer, a Phase 3 randomized study concluded in the Journal of Clinical Oncology online February 13.

Next post in Breast Cancer